Meyhoff H H, Gerstenberg T C, Nordling J
Br J Urol. 1983 Feb;55(1):34-7. doi: 10.1111/j.1464-410x.1983.tb07075.x.
In a randomised double-blind cross-over trial of 19 females with motor urge incontinence but without bladder suspension defect, the effects of 14 days' treatment with emepronium bromide 200 mg qid, flavoxate chloride 200 mg qid or placebo qid were compared by means of micturition charts, the patients' drug preferences and evaluation of side effects. Placebo was the only drug giving rise to a statistically significant decrease in the frequency of voidings, incontinence and nocturia. Forty-seven per cent of the patients preferred placebo and side effects were less frequent during treatment with this medication. No differences could be demonstrated between the effects of emepronium bromide and flavoxate chloride. Perhaps detrusor instability is not always the main reason for the voiding dysfunction in these patients, in whom the effect of placebo was equal or superior to the effect of "active drugs" and superior to no treatment at all.
在一项针对19名有尿急失禁但无膀胱悬吊缺陷的女性进行的随机双盲交叉试验中，通过排尿图表、患者对药物的偏好以及副作用评估，比较了每日4次服用200毫克溴化依米普明、每日4次服用200毫克氯黄酮酯或每日4次服用安慰剂，治疗14天的效果。安慰剂是唯一一种使排尿频率、失禁和夜尿次数在统计学上显著减少的药物。47%的患者更喜欢安慰剂，且使用这种药物治疗期间副作用较少。溴化依米普明和氯黄酮酯的效果之间未显示出差异。或许逼尿肌不稳定并不总是这些患者排尿功能障碍的主要原因，在这些患者中，安慰剂的效果等同于或优于“活性药物”，且优于不进行任何治疗。
